Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
Status:
Active, not recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effectiveness (how well the drugs work), safety, and
tolerability of the investigational drug combination of olaparib and AZD6738 for all patients
with metastatic castration-resistant prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center